南非 - 英文 - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - injection - see ingredients - each vial contains cefuroxime sodium equivalent to 1,5 g cefuroxime

美国 - 英文 - NLM (National Library of Medicine)

sagent pharmaceuticals - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin injection is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa . ciprofloxacin injection is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis . ciprofloxacin injection is indicated in adult patients for treatment of nosocomial pneumonia caused by haemop

美国 - 英文 - NLM (National Library of Medicine)

sagent pharmaceuticals - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin injection is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa . ciprofloxacin injection is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis . ciprofloxacin injection is indicated in adult patients for treatment of nosocomial pneumonia caused by haemop

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefuroxime sodium 1577.8mg equivalent to cefuroxime 1500 mg - powder for injection - 1.5 g - active: cefuroxime sodium 1577.8mg equivalent to cefuroxime 1500 mg

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefuroxime sodium 263mg equivalent to cefuroxime 250 mg - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to cefuroxime 250 mg

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefuroxime sodium 788.9mg equivalent to cefuroxime 750 mg - powder for injection - 750 mg - active: cefuroxime sodium 788.9mg equivalent to cefuroxime 750 mg

美国 - 英文 - NLM (National Library of Medicine)

mylan institutional llc - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - moxifloxacin is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3)] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4)]. moxifloxacin is indicated in adult patients for the treatment of complic

美国 - 英文 - NLM (National Library of Medicine)

rebel distributors corp - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 400 mg in 40 ml - ciprofloxacin injection, usp is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. please see dosage and administration for specific recommendations. adult patients:   urinary tract infections caused by escherichia coli (including cases with secondary bacteremia), klebsiella pneumoniae subspecies pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter diversus , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . lower respiratory infections caused by escherichia coli , klebsiella pneumoniae subspecies pneumoniae , enterobacter cloacae , proteus mirabilis , pseudomonas aeruginosa , haemophilus

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - clarithromycin - oral suspension - 25mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - clarithromycin - oral suspension - 50mg/1ml